PRINCETON, NJ - 10/23/2018 (PRESS RELEASE JET)
Bionpharma® Inc, Princeton, NJ - Bionpharma Inc., a New Jersey headquartered pharmaceutical company, announced that it has received final FDA approval for a generic version of both ONFI® (Clobazam) Tablets (10 & 20mg) and Oral Suspension (2.5mg/mL). Clobazam is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Both of Bionpharma’s Clobazam Tablets and Suspension are manufactured in the USA and is available to consumers.
Bill Winter, EVP- Sales and Distribution added, “Clobazam is Bionpharma’s first launch on the day of expiry of exclusivity. These products are a good addition to the growing portfolio of Bionpharma and is another testament to the company’s endeavor to provide high quality, affordable generics to the US healthcare system.”
According to IQVIA™, U.S market annual sales for the 12 months ended August 2018 for Clobazam Tablets, 10 and 20mg and Clobazam Oral Suspension, 2.5mg/mL is estimated to be approximately $594 Million and $255 Million respectively.
Bionpharma is a pharmaceutical company backed and built by seasoned management professionals in the Global Generics business with cumulative experience of more than 100 years. Based out of Princeton, NJ and with offices in Raleigh, NC, Bionpharma is focused on developing and commercializing complex generic products. Being one of the largest suppliers of soft gelatin capsules products in the United States in both the Rx and OTC pharmaceutical space, Bionpharma markets directly to customers and also engages with strategic partners for prescription and “Rx-to-OTC switch” products (non-monograph OTC). With a strong portfolio of differentiated dosage form generic products having a significant market share, Bionpharma is accomplished in the areas of Product Development, Regulatory Affairs, Quality Management, Sales and Distribution and Supply Chain Management, working with partners across the globe.